Barbier, Liese http://orcid.org/0000-0003-1786-2080
Declerck, Paul
Simoens, Steven http://orcid.org/0000-0002-9512-2005
Neven, Patrick
Vulto, Arnold G.
Huys, Isabelle
Article History
Received: 13 May 2018
Revised: 11 April 2019
Accepted: 24 April 2019
First Online: 1 July 2019
Competing interests
: S.S. is involved in a stakeholder roundtable on biosimilars sponsored by Amgen, Pfizer and MSD, and has participated in an advisory board meeting on biosimilars for Pfizer. A.G.V. is involved in consulting, advisory work and speaking engagements for a number of companies, i.e., AbbVie, Accord, Amgen, Biogen, EGA, Pfizer/Hospira, Mundipharma, Roche, Novartis, Sandoz, Boehringer Ingelheim. PD participated at advisory board meetings for AbbVie, Amgen, Hospira, and Samsung Bioepis and is on the Speakers’ Bureau of AbbVie, Celltrion, Hospira, Merck Serono, and Roche. P.N. and L.B. declare no conflict of interest. The preliminary results of this research were presented at an Amgen sponsored Satellite Symposium at the 22nd Congress of the EAHP (Cannes, France, 2017). LB declares that the research was conducted in the absence of any commercial or financial relationship that could be perceived as a potential conflict of interest.
: Not applicable
: Not Applicable
: This manuscript is funded by KU Leuven and the Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL Fund).